Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 4/20 | 0.43 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.42 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.42 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | WDR5 | P61964 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13302415 | 0.81 | SOS1 (0.44) | HTTSMN1; SMN2SOS1CSNK2A2CSNK2B | |
| SCHEMBL13302154 | 0.78 | PTPN1 (0.49) | SMN1; SMN2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL13302155 | 0.76 | MAPT (0.51) | SMN1; SMN2NR4A2KDM4EALDH1A1MAPT | |
| SCHEMBL5429949 | 0.73 | PBRM1 (0.51) | HTTSMN1; SMN2NR4A2KDM4EALDH1A1 | |
| SCHEMBL13302169 | 0.72 | SMN1; SMN2 (0.44) | HTTSMN1; SMN2ARCSNK2A2CSNK2B | |
| SCHEMBL13302188 | 0.72 | KDM5A (0.49) | HTTSMN1; SMN2CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL13302186 | 0.72 | CA12 (0.46) | HTTSMN1; SMN2SOS1CSNK2A2CSNK2B | |
| SCHEMBL11871562 | 0.72 | CSNK2A2 (0.41) | HTTSMN1; SMN2SOS1CSNK2A2CSNK2B | |
| SCHEMBL13302161 | 0.71 | MAPT (0.43) | HTTSMN1; SMN2ARKDM4EALDH1A1 | |
| SCHEMBL2811213 | 0.71 | HTT (0.59) | HTTSMN1; SMN2CSNK2A2CSNK2BCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362066-B2 | Compounds and methods for treating protein folding disorders | TREVENTIS CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | SNCA, MAPT, APP | HTT 5/4885SMN1; SMN2 141/4885AR 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.